583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model

J.A Perez Fidalgo,A Cervantes,J Hochstadt,M Mendiola,I Teruel,B Pineda Merlo,S Guerra Ojeda,J.J Martinez Pretel,A Bernat,P Sanchez-Serrano,O Burgués,A Redondo Sanchez,M Gil Martín,M Romeo Marin,V Heredia

doi:10.1016/j.annonc.2022.07.711

583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model

J.A Perez Fidalgo, A Cervantes + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.711

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Hospital Universitario La Paz, Institut Català d'Oncologia, University of Valencia, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

#High Grade Ovarian Cancer #PARP Inhibitors Resistance + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Despite benefit of PARP inhibitors (PARPi) in high grade ovarian cancer (HGOC) a proportion of patients will become resistant. The aim of our study was to assess if AURKA overexpression is a mechanism of PARPi resistant and if the inhibition with alisertib (ALI) could overcome resistance to olaparib (OLA) in cell line models.

Full Text